Novel ALL treatment strategies: inotuzumab ozogamicin

Novel therapeutic strategies in ALLПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Exploring novel treatment strategies for Ph-like ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

What’s next for inotuzumab ozogamicin in ALL?Подробнее

Novel ALL treatment strategies: CAR T-cellsПодробнее

Novel ALL treatment strategies: blinatumomabПодробнее

Improving adult ALL treatment: pediatric regimens & adding inotuzumabПодробнее

Improving the SOC for ALL with inotuzumabПодробнее

Clinical trials in acute lymphoblastic leukemiaПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Novel drugs and treatment strategies for myelofibrosisПодробнее

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALLПодробнее

Inotuzumab ozogamicin with bosutinib for Ph+ ALL and CMLПодробнее

Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALLПодробнее

Novel targeted antibodies for R/R B-ALLПодробнее

Dr. Brammer on Data With Inotuzumab Ozogamicin in ALLПодробнее

Safety and efficacy of blinatumomab and inotuzumab ozogamicin in multiple relapsed ALLПодробнее